For the Inventor, By the Inventor

Enter assignee name

Daiichi Sankyo Company, Limited

USPTO Granted Patents = 440

CIPO Patents = 503

EPO Patents = 298

Trademarks = 157

Forward Citations = 1,519

Loading Chart...

Loading Chart...

1,344 inventors (with patents filed for the assignee):

Kensuke Nakamura (23 out of 39 patents)

Kazumasa Aoki (20 out of 35 patents)

Yuji Kasuya (18 out of 23 patents)

4. Takeshi Masuda (17 out of 50 patents)

5. Shinji Ashida (17 out of 17 patents)

6. Takashi Nakada (15 out of 18 patents)

7. Koji Morita (14 out of 40 patents)

8. Makoto Koizumi (14 out of 49 patents)

9. Katsuyoshi Nakajima (13 out of 16 patents)

10. Hiroyuki Naito (13 out of 43 patents)

11. Keiji Saito (13 out of 25 patents)

12. Yasuyuki Ogawa (13 out of 35 patents)

13. Masao Yoshida (12 out of 31 patents)

14. Yoshiharu Hiruma (12 out of 13 patents)

15. Eisuke Tsuda (12 out of 25 patents)

Core Competencies:

Antibody-Drug Conjugates

Bispecific Antibody

Cyclic Dinucleotide Derivative

Claudin-6 Antibody

MUC1 Antibody

Glycogen Storage Disease

Retinal Degenerative Disease

Protein Biomarker

Peptide Therapeutics

Cancer Treatment

Immune Checkpoint Inhibitor

Nucleic Acid Biomarker

440 patents: Sort by Forward Citations

1. 12390455 - EZH1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug (2025-08-19),

2. 12378260 - Benzotriazole compound (2025-08-05),

3. 12370263 - Cyclic dinucleotide derivative based antibody-drug conjugates (2025-07-29),

4. 12358999 - Protein recognizing drug moiety of antibody-drug conjugate (2025-07-15),

5. 12350344 - Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate (2025-07-08),

6. 12344674 - Bispecific antibody (2025-07-01),

7. 12319736 - Combination of antibody-drug conjugate and immune checkpoint inhibitor (2025-06-03),

8. 12312641 - Sensitivity marker for antibody-drug conjugate (2025-05-27),

9. 12297187 - Compound having cyclic structure (2025-05-13),

10. 12291577 - Anti-MUC1 antibody-drug conjugate (2025-05-06),

11. 12246196 - Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines (2025-03-11),

12. 12240855 - Pyrrolopyrazole derivative (2025-03-04),

13. 12233155 - Polynucleotides encoding antibodies which bind the EC3 domain of cadherin-6 (CDH6) and possess internalization ability (2025-02-25),

14. 12220604 - Treatment of metastatic brain tumor by administration of an antibody-drug conjugate (2025-02-11),

15. 12186310 - Antibody-drug conjugate (2025-01-07),

Daiichi Sankyo Company, Limited is a global pharmaceutical company based in Tokyo, Japan. It focuses on developing innovative therapies to improve the health and well-being of people worldwide. With a rich heritage of scientific expertise, Daiichi Sankyo aims to address unmet medical needs by delivering breakthrough medicines. The company's key areas of focus include oncology, cardiovascular, and renal diseases, as well as immune and inflammatory disorders. Through strategic partnerships and collaborations, Daiichi Sankyo strives to advance medical science and make a positive impact on patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

440 Patents

#181 in Tokyo

#402 in Japan

#2,093 in the World

Daiichi Sankyo Company, Limited

Forward Citations = 1,519

1,344 inventors:

Kensuke Nakamura (23 out of 39 patents)

Kazumasa Aoki (20 out of 35 patents)

Yuji Kasuya (18 out of 23 patents)

4. Takeshi Masuda (17 out of 50 patents)

5. Shinji Ashida (17 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…